Premium
Mobile health tools for the management of chronic respiratory diseases
Author(s) -
Sleurs Kristien,
Seys Sven F.,
Bousquet Jean,
Fokkens Wytske J.,
Gorris Senne,
Pugin Benoit,
Hellings Peter W.
Publication year - 2019
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.13720
Subject(s) - asthma , medicine , digital health , mobile apps , health care , empowerment , mobile technology , copd , chronic disease , physical therapy , family medicine , mobile device , world wide web , computer science , political science , law , economics , economic growth
Background The market of mobile health ( mH ealth) technology is rapidly evolving, making new mobile technologies potentially available for healthcare systems. Patient empowerment through self‐monitoring of symptoms, shared decision making with the physician, and easily accessible education are important features extending the reach of mH ealth technology beyond traditional care. Methods Two digital distribution platforms (Apple App Store and Google Play Store) were searched for currently available mobile applications (apps) for patients with chronic respiratory diseases ( CRD s). A new index (score ranging from 0 to 10) was developed to assess the potential of apps as a tool to empower patients through mobile technology (based on self‐monitoring, personalized feedback, and patient education app features). Results One hundred and twelve apps were retained for analysis and could be classified in 5 categories: Asthma (n = 71), COPD (n = 15), Asthma and COPD (n = 15), Rhinitis and Asthma (n = 5), and Rhinosinusitis (n = 6). Eighty percent were developed by medical technology companies compared to 18% by medical doctors and 2% by pharmaceutical companies. Two‐thirds of apps allow disease self‐monitoring, whereas over half of apps provide patient feedback through graphs. Sixty percent of apps contain easily accessible patient education material. Only three percent of apps reach a score of ≥7 on the newly designed patient empowerment index. Conclusions A variety of apps are available for patients with CRD s of which only few were developed by or jointly with medical doctors. The majority of these apps include self‐monitoring tools, but only few also provide personalized feedback, which is needed to adopt these apps into daily care.